Immutep Limited (ASX:IMM) Insider Acquires A$624,000.00 in Stock

Immutep Limited (ASX:IMM) insider Marc Voigt bought 2,400,000 shares of the company’s stock in a transaction on Thursday, April 3rd. The stock was bought at an average cost of A$0.26 ($0.16) per share, with a total value of A$624,000.00 ($385,185.19).

Immutep Price Performance

The company has a market cap of $465.79 million, a price-to-earnings ratio of -6.92, a price-to-earnings-growth ratio of -5.92 and a beta of 1.93. The company has a debt-to-equity ratio of 0.90, a current ratio of 13.81 and a quick ratio of 13.78.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.